Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines (Q37140636)

18 August 2017

1 reference

title

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines (English)

1 reference

18 August 2017

1 reference

Cornelis J. M. Melief

series ordinal

object named as

Cornelis J M Melief

1 reference

18 August 2017

Sjoerd H van der Burg

series ordinal

object named as

Sjoerd H van der Burg

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

published in

Nature Reviews Cancer

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

351-360

1 reference

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

18 August 2017

cites work

1 reference

Vaccination for treatment and prevention of cancer in animal models.

31 March 2020

1 reference

Design and development of synthetic peptide vaccines: past, present and future

31 March 2020

1 reference

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

31 March 2020

1 reference

Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine

31 March 2020

1 reference

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

31 March 2020

1 reference

Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model

31 March 2020

1 reference

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

31 March 2020

1 reference

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

31 March 2020

1 reference

Recombinant viral vectors: cancer vaccines

31 March 2020

1 reference

Cancer vaccines: moving beyond current paradigms

31 March 2020

1 reference

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

31 March 2020

1 reference

Therapeutic immunization for HIV.

31 March 2020

1 reference

Therapeutic vaccination in chronic hepatitis B virus carriers

31 March 2020

1 reference

Dendritic cell immunotherapy: mapping the way.

31 March 2020

1 reference

31 March 2020

DC-based cancer vaccines

1 reference

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

31 March 2020

1 reference

Dendritic cell subsets in health and disease.

31 March 2020

1 reference

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells

31 March 2020

1 reference

DNA vaccines: precision tools for activating effective immunity against cancer.

31 March 2020

1 reference

Medicinal application of long synthetic peptide technology

31 March 2020

1 reference

Dominant determinants in hen eggwhite lysozyme correspond to the cryptic determinants within its self-homologue, mouse lysozyme: implications in shaping of the T cell repertoire and autoimmunity

31 March 2020

1 reference

Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design

31 March 2020

1 reference

Vaccinia virus immune evasion

31 March 2020

1 reference

Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide

31 March 2020

1 reference

Peptide-induced antiviral protection by cytotoxic T cells

31 March 2020

1 reference

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

31 March 2020

1 reference

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide

31 March 2020

1 reference

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

31 March 2020

1 reference

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells

31 March 2020

1 reference

Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

31 March 2020

1 reference

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

31 March 2020

1 reference

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity

31 March 2020

1 reference

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

31 March 2020

1 reference

Strategies for immunotherapy of cancer

31 March 2020

1 reference

Cross-presentation, dendritic cells, tolerance and immunity

31 March 2020

1 reference

Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants

31 March 2020

1 reference

Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity

31 March 2020

1 reference

Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

31 March 2020

1 reference

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

31 March 2020

1 reference

Heteroclitic immunization induces tumor immunity

31 March 2020

1 reference

Peptide vaccines for cancer

31 March 2020

1 reference

On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor beta chain

31 March 2020

1 reference

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

31 March 2020

1 reference

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

31 March 2020

1 reference

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

31 March 2020

1 reference

Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone

31 March 2020

1 reference

T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides

31 March 2020

1 reference

Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.

31 March 2020

1 reference

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

31 March 2020

1 reference

Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity

31 March 2020

1 reference

Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells

31 March 2020

1 reference

Balance of Th1/Th2 cytokines associated with the preventive effect of incomplete Freund's adjuvant on the development of adjuvant arthritis in LEW rats

31 March 2020

1 reference

Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant

31 March 2020

1 reference

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

31 March 2020

1 reference

Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes

31 March 2020

1 reference

Role of Toll-like receptors in costimulating cytotoxic T cell responses

31 March 2020

1 reference

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

31 March 2020

1 reference

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

31 March 2020

1 reference

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

31 March 2020

1 reference

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

31 March 2020

1 reference

In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells

31 March 2020

1 reference

Active-specific immunization against melanoma: is the problem at the receiving end?

31 March 2020

1 reference

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

31 March 2020

1 reference

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

31 March 2020

1 reference

Longevity of Antigen Presentation and Activation Status of APC Are Decisive Factors in the Balance Between CTL Immunity Versus Tolerance

31 March 2020

1 reference

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

31 March 2020

1 reference

Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus

31 March 2020

1 reference

CpG-DNA aided cross-presentation of soluble antigens by dendritic cells

31 March 2020

1 reference

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells

31 March 2020

1 reference

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses

31 March 2020

1 reference

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity

31 March 2020

1 reference

Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid

31 March 2020

1 reference

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

31 March 2020

1 reference

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines

31 March 2020

1 reference

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct

31 March 2020

1 reference

Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition.

31 March 2020

1 reference

Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination

31 March 2020

1 reference

Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens

31 March 2020

1 reference

Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules

31 March 2020

1 reference

T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides

31 March 2020

1 reference

B cells directly tolerize CD8(+) T cells

31 March 2020

1 reference

Sustained response initiation is required for T cell clonal expansion but not for effector or memory development in vivo.

31 March 2020

1 reference

Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation.

31 March 2020

1 reference

A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes

31 March 2020

1 reference

An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself

31 March 2020

1 reference

CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes

31 March 2020

1 reference

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

31 March 2020

1 reference

Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen

31 March 2020

1 reference

Design and evaluation of antigen-specific vaccination strategies against cancer.

31 March 2020

1 reference

Epitope repertoire of human CD4+ lines propagated with tetanus toxoid or with synthetic tetanus toxin sequences

31 March 2020

1 reference

Combined chemoimmunotherapy of solid tumours: improving vaccines?

31 March 2020

1 reference

Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy

31 March 2020

1 reference

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

31 March 2020

1 reference

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

31 March 2020

1 reference

Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif

31 March 2020

1 reference

Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

31 March 2020

1 reference

Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2373

1 reference

Dimensions Publication ID

18 August 2017

1032868784

0 references

1 reference